SUVEN LIFE SCIENCES LTD
Add to watch list to get report alerts
BSE Code:
530239
NSE Code:
SUVEN
Business Profile
Business Profile
Suven Life Sciences (SLS) is a Hyderabad-based bulk pharmaceutical company promoted by Venkat Jasti. Suven Life Sciences was established in 1989 as a Private Sector Organization and was converted into Public Sector Company in January 1995.
SLS is engaged in contract research and manufacturing services (CRAMS), drug discovery and development support services and clinical research and data management services. SLS has facilities in Suryapet, Jeedimetla and Pashamylaram in Hyderabad. The company has several 100% subsidiaries including Suven Synthesis, a US FDA-compliant plant for the manufacture of IPR linked ANDA based APIs; Synthon Chiragenics, a New Jersey based acquisition for carbohydrate-based chiral chemistry.
Financials
Suven Life Sciences registered a 53.41% decline in net profits to Rs 11.59 million for the quarter ended in September 2007 from a profit of Rs 24.88 million for the quarter ended in September 2006.
Net Sales dipped 0.15 % to Rs 248.41 million for the quarter ended September 2007 from Rs 278.84 million for the quarter ended September 2006.
Total income rose 6.93 % to Rs 299.09 million for the quarter ended September 2007, from Rs 279.7 million for the quarter ended September 2006.
The earnings per share (EPS) of the company stood at Rs 0.10 in the quarter ended September 2007.
Recent Developments
24-MAR-08
Hyderabad-based drug maker Suven Life Sciences said on Monday that two of its new chemical entities have been granted patents in Eurasia region.
27-NOV-07
Suven Life Sciences (Suven) announced that the European Patent Office (EPO) granted two patents (1523486 and 1581538) to the company, valid until June 2022. The granted patent are for class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer`s, attention deficient hyperactivity, Huntington`s disease, Parkinson & Schizophrenia
05-NOV-07
Suven Life Sciences is showcasing its research on some new chemical entities (NCEs) with applications in neuroscience at the annual meeting of the Society for Neuroscience (SFN) currently being held at San Diego, USA from November 3 to 7. Suven is presenting new data of its NCEs in the five areas of neuroscience viz. Alzheimer?s, schizophrenia, Parkinson, sleep and obesity diseases for which it had been granted nine product patents (two from EU, three from India, two from Australia and two from New Zealand). One of the focus areas for Suven?s discovery research team is central nervous system (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Its discovery scientists here are currently pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer?s Schizophrenia, and cognitive disorders, sleep, neurodegeneration and obesity through CNS targets.
31-OCT-07
Suven Life Sciences announced that two of their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases were granted patents in Australia (2003-249582 and 2003-249583) and New Zealand (537770 and 537772) and these patents are valid until 2022.
Future Plans
In the next year, SLS plans to initiate clinical trials for a drug for Alzheimer`s disease. The company will also file for IND for its diabetes drug and increase the drug discovery activity for other indications of CNS.